Cargando…

Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire

BACKGROUND: Phenylketonuria (PKU) is a rare genetic disorder caused by a defect in the metabolism of phenylalanine (PHE) resulting in elevated blood and brain PHE levels, and leading to cognitive, emotional, and psychosocial problems. The phenylketonuria – quality of life (PKU-QOL) questionnaire was...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurecki, Elaina, Cunningham, Amy, Birardi, Vanessa, Gagol, Grégory, Acquadro, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343404/
https://www.ncbi.nlm.nih.gov/pubmed/28274259
http://dx.doi.org/10.1186/s12955-017-0620-1
_version_ 1782513357287325696
author Jurecki, Elaina
Cunningham, Amy
Birardi, Vanessa
Gagol, Grégory
Acquadro, Catherine
author_facet Jurecki, Elaina
Cunningham, Amy
Birardi, Vanessa
Gagol, Grégory
Acquadro, Catherine
author_sort Jurecki, Elaina
collection PubMed
description BACKGROUND: Phenylketonuria (PKU) is a rare genetic disorder caused by a defect in the metabolism of phenylalanine (PHE) resulting in elevated blood and brain PHE levels, and leading to cognitive, emotional, and psychosocial problems. The phenylketonuria – quality of life (PKU-QOL) questionnaire was the first self-administered disease-specific instrument developed to assess the impact of PKU and its treatment on the health-related quality of life (HRQL) of patients and their caregivers. Available in four versions (child, adolescent, adult and parent), the PKU-QOL was simultaneously developed and validated in seven countries [i.e., France, Germany, Italy, The Netherlands, Spain, Turkey and the United Kingdom (UK)]. The objectives of our study were to develop and linguistically validate the PKU-QOL questionnaire for use in the United States (US). METHODS: The UK versions served as a basis for the development of the US English PKU-QOL questionnaire. The linguistic validation process consisted of 4 steps: 1) adaptation of the UK versions into US English by a translator native of US English and living in the US; 2) a clinician review; 3) cognitive interviews with patients and caregivers to test the appropriateness, understandability and clarity of the US translations; and 4) two proof-readings. RESULTS: The adaptation from UK to US English revealed the usual syntactic and idiomatic differences between the two languages, such as differences in: 1) Spelling, e.g., “dietician” (UK) vs. “dietitian” (US), or “mum” (UK) vs. “mom” (US); 2) Syntax or punctuation; and 3) Words/expressions use, e.g., “holidays” (UK) vs. “vacation” (US), or “biscuits” (UK) vs. “crackers” (US). The major issue was cultural, and consisted of using a different terminology to describe PKU treatment throughout the questionnaires. The clinician, with the patients and the caregivers, during the interviews suggested to replace “supplement and amino-acid mixture” or “supplements” with “medical formula.” This wording was later changed to “medical food” to be consistent with the terminology used in current US published guidelines. CONCLUSIONS: The translation of the UK English PKU-QOL questionnaire into US English did not raise critical semantic and cultural issues. The PKU-QOL will be valuable for US healthcare providers in individualizing treatment and managing patients with PKU.
format Online
Article
Text
id pubmed-5343404
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53434042017-03-10 Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire Jurecki, Elaina Cunningham, Amy Birardi, Vanessa Gagol, Grégory Acquadro, Catherine Health Qual Life Outcomes Research BACKGROUND: Phenylketonuria (PKU) is a rare genetic disorder caused by a defect in the metabolism of phenylalanine (PHE) resulting in elevated blood and brain PHE levels, and leading to cognitive, emotional, and psychosocial problems. The phenylketonuria – quality of life (PKU-QOL) questionnaire was the first self-administered disease-specific instrument developed to assess the impact of PKU and its treatment on the health-related quality of life (HRQL) of patients and their caregivers. Available in four versions (child, adolescent, adult and parent), the PKU-QOL was simultaneously developed and validated in seven countries [i.e., France, Germany, Italy, The Netherlands, Spain, Turkey and the United Kingdom (UK)]. The objectives of our study were to develop and linguistically validate the PKU-QOL questionnaire for use in the United States (US). METHODS: The UK versions served as a basis for the development of the US English PKU-QOL questionnaire. The linguistic validation process consisted of 4 steps: 1) adaptation of the UK versions into US English by a translator native of US English and living in the US; 2) a clinician review; 3) cognitive interviews with patients and caregivers to test the appropriateness, understandability and clarity of the US translations; and 4) two proof-readings. RESULTS: The adaptation from UK to US English revealed the usual syntactic and idiomatic differences between the two languages, such as differences in: 1) Spelling, e.g., “dietician” (UK) vs. “dietitian” (US), or “mum” (UK) vs. “mom” (US); 2) Syntax or punctuation; and 3) Words/expressions use, e.g., “holidays” (UK) vs. “vacation” (US), or “biscuits” (UK) vs. “crackers” (US). The major issue was cultural, and consisted of using a different terminology to describe PKU treatment throughout the questionnaires. The clinician, with the patients and the caregivers, during the interviews suggested to replace “supplement and amino-acid mixture” or “supplements” with “medical formula.” This wording was later changed to “medical food” to be consistent with the terminology used in current US published guidelines. CONCLUSIONS: The translation of the UK English PKU-QOL questionnaire into US English did not raise critical semantic and cultural issues. The PKU-QOL will be valuable for US healthcare providers in individualizing treatment and managing patients with PKU. BioMed Central 2017-03-09 /pmc/articles/PMC5343404/ /pubmed/28274259 http://dx.doi.org/10.1186/s12955-017-0620-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Jurecki, Elaina
Cunningham, Amy
Birardi, Vanessa
Gagol, Grégory
Acquadro, Catherine
Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title_full Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title_fullStr Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title_full_unstemmed Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title_short Development of the US English version of the phenylketonuria – quality of life (PKU-QOL) questionnaire
title_sort development of the us english version of the phenylketonuria – quality of life (pku-qol) questionnaire
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343404/
https://www.ncbi.nlm.nih.gov/pubmed/28274259
http://dx.doi.org/10.1186/s12955-017-0620-1
work_keys_str_mv AT jureckielaina developmentoftheusenglishversionofthephenylketonuriaqualityoflifepkuqolquestionnaire
AT cunninghamamy developmentoftheusenglishversionofthephenylketonuriaqualityoflifepkuqolquestionnaire
AT birardivanessa developmentoftheusenglishversionofthephenylketonuriaqualityoflifepkuqolquestionnaire
AT gagolgregory developmentoftheusenglishversionofthephenylketonuriaqualityoflifepkuqolquestionnaire
AT acquadrocatherine developmentoftheusenglishversionofthephenylketonuriaqualityoflifepkuqolquestionnaire